Abstract
Intrigued by the role of protein acetylation in hepatitis C virus (HCV) replication, we tested known histone deacetylase (HDAC) inhibitors and a focused library of structurally simple hydroxamic acids for inhibition of a HCV subgenomic replicon. While known HDAC inhibitors with varied inhibitory profiles proved to be either relatively toxic or ineffective, structure-activity relationship (SAR) studies on cinnamic hydroxamic acid and benzo[b]thiophen-2-hydroxamic acid gave rise to compounds 22 and 53, which showed potent and selective anti-HCV activity and therefore are promising starting points for further structural optimization and mechanistic studies.
Original language | English (US) |
---|---|
Pages (from-to) | 785-800 |
Number of pages | 16 |
Journal | Journal of medicinal chemistry |
Volume | 58 |
Issue number | 2 |
DOIs | |
State | Published - Jan 22 2015 |
Bibliographical note
Publisher Copyright:© 2014 American Chemical Society.